Genetron Holdings Limited – NASDAQ:GTH
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 6 hours
Genetron Holdings Limited stock price monthly change
+2.70%
month
Genetron Holdings Limited stock price quarterly change
+2.70%
quarter
Genetron Holdings Limited stock price yearly change
+242.34%
year
Genetron Holdings Limited key metrics
Market Cap | 127.28M |
Enterprise value | N/A |
P/E | -0.84 |
EV/Sales | -0.15 |
EV/EBITDA | 0.13 |
Price/Sales | 0.99 |
Price/Book | 0.61 |
PEG ratio | N/A |
EPS | -17.23 |
Revenue | 650.70M |
EBITDA | -651.75M |
Income | -801.96M |
Revenue Q/Q | 37.07% |
Revenue Y/Y | 22.32% |
Profit margin | -128.09% |
Oper. margin | -120.31% |
Gross margin | 55.99% |
EBIT margin | -120.31% |
EBITDA margin | -100.16% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeGenetron Holdings Limited stock price history
Genetron Holdings Limited stock forecast
Genetron Holdings Limited financial statements
| Mar 2022 | 110.32M | -168.47M | -152.71% |
|---|---|---|---|
| Jun 2022 | 137.74M | -234.67M | -170.36% |
| Sep 2022 | 201.31M | -199.40M | -99.05% |
| Dec 2022 | 201.31M | -199.40M | -99.05% |
| Sep 2021 | 1652019000 | 261.28M | 15.82% |
|---|---|---|---|
| Dec 2021 | 1517619000 | 307.56M | 20.27% |
| Mar 2022 | 1328633000 | 288.54M | 21.72% |
| Jun 2022 | 1303365000 | 408.44M | 31.34% |
| Dec 2022 | 0 | 0 | 0 |
|---|---|---|---|
| Mar 2023 | 0 | 0 | 0 |
| Jun 2023 | 0 | 0 | 0 |
| Sep 2023 | 0 | 0 | 0 |
Genetron Holdings Limited alternative data
| Aug 2023 | 993 |
|---|---|
| Sep 2023 | 993 |
| Oct 2023 | 993 |
| Nov 2023 | 993 |
| Dec 2023 | 993 |
| Jan 2024 | 993 |
| Feb 2024 | 993 |
| Mar 2024 | 993 |
| Apr 2024 | 993 |
| May 2024 | 993 |
| Jun 2024 | 993 |
| Jul 2024 | 993 |
Genetron Holdings Limited other data
1.92%
-0.41%
of GTH is owned by hedge funds
8.89M
-1.84M
shares is hold by hedge funds
| Quarter | Transcript |
|---|---|
| Q1 2022 2 Jun 2022 | Q1 2022 Earnings Call Transcript |
| Q4 2021 29 Mar 2022 | Q4 2021 Earnings Call Transcript |
| Q2 2021 24 Aug 2021 | Q2 2021 Earnings Call Transcript |
| Q1 2021 24 May 2021 | Q1 2021 Earnings Call Transcript |
-
When is Genetron Holdings Limited's next earnings date?
Unfortunately, Genetron Holdings Limited's (GTH) next earnings date is currently unknown.
-
Does Genetron Holdings Limited pay dividends?
No, Genetron Holdings Limited does not pay dividends.
-
How much money does Genetron Holdings Limited make?
Genetron Holdings Limited has a market capitalization of 127.28M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 22.32% to 650.71M US dollars.
-
What is Genetron Holdings Limited's stock symbol?
Genetron Holdings Limited is traded on the NASDAQ under the ticker symbol "GTH".
-
What is Genetron Holdings Limited's primary industry?
Company operates in the Healthcare sector and Medical - Diagnostics & Research industry.
-
How do i buy shares of Genetron Holdings Limited?
Shares of Genetron Holdings Limited can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does Genetron Holdings Limited have?
As Jul 2024, Genetron Holdings Limited employs 993 workers.
-
When Genetron Holdings Limited went public?
Genetron Holdings Limited is publicly traded company for more then 5 years since IPO on 15 Jun 2020.
-
What is Genetron Holdings Limited's official website?
The official website for Genetron Holdings Limited is genetronhealth.com.
-
How can i contact Genetron Holdings Limited?
Genetron Holdings Limited can be reached via phone at +86 10 5090 7500.
Genetron Holdings Limited company profile:
Genetron Holdings Limited
genetronhealth.comExchange:
NASDAQ
Full time employees:
993
Industry:
Medical - Diagnostics & Research
Sector:
Healthcare
Genetron Holdings Limited, a precision oncology company, engages in the cancer molecular profiling, and harnessing technologies in molecular biology and data science for cancer treatment. The company offers diagnosis and monitoring services, and early screening services through laboratory developed tests services. It also provides in-vitro diagnostic products, including 8-gene lung cancer assay, an IVD assay product to detect lung cancer; Genetron 3D biochip reading instrument; Genetron S5, a semiconductor-based NGS system, which detects the nucleotide through detecting the change in pH; Genetron Chef System; Genetron S2000 platform, a production-scale sequencer; and Onco PanScan, a genomic profiling service for various solid tumors. In addition, it offers IDH1 and TERT gene assays for glioma; thyroid basic assay for thyroid tumor; platelet-derived growth factor receptor alpha assay for GIST cancer; and HCCscan, a qPCR-based assay to detect hepatocellular carcinoma. Further, it provides development services in the areas of genomics research and clinical development in collaboration with biopharmaceutical companies worldwide. The company has a strategic partnership with JD Health to create solutions for full-cycle cancer management. Genetron Holdings Limited was founded in 2015 and is headquartered in Beijing, the People's Republic of China.
Building 11
Beijing, 102206
Beijing, 102206
CIK: 0001782594
ISIN: US37186H2094
CUSIP: 37186H100
